Wellspring Worldwide, Inc.

Patent attorney business Symbiosis IP has expanded its intellectual property (IP) and patent services following the appointment of IP licensing and commercialisation specialists Dr Amy Lam and Dr Andrew Tingey. Amy Lam, who joins as associate director – Consulting & IP transactions, and Andrew Tingey, who joins as director – Licensing & IP transactions, will complement Symbiosis IP’s existing specialisms within patent protection and life sciences to support clients in understanding, leveraging, and realising the value of their IP. Combined with the IP and commercial teams at Gateley, the professional services business that acquired Symbiosis IP, and Adamson Jones, another patent and trade mark attorney business within Gateley, Lam and Tingey can help provide comprehensive, end-to-end commercial, IP valuation, and licensing strategy services to clients across a range of sectors, including life sciences, chemicals, and fintech. “I’m pleased to welcome Amy and Andrew, who bring a combined 40 years’ experience in IP licensing and commercialisation,” said Symbiosis IP director Rob Docherty. “Their appointments will enhance the existing services provided by Symbiosis IP, Adamson Jones, and Gateley’s legal business, Gateley Legal, to support clients in realising the full commercial value of their IP.” Previously a principal consultant and head of the Scotland office at Wellspring, Lam specialises in IP management and strategy, business development, and early-stage commercialisation across life sciences, and has experience supporting IP commercialisation in other sectors, such as software-as-a-service (SaaS). She led on and supported more than 120 life science consulting projects for public and private sector clients, covering innovations such as pharmaceuticals, genome editing, cell therapy, and medical diagnostics. “Clients often understand the need for IP within their operations, without appreciating its potential to expand and enhance the value of their inventions,” Lam said. “Symbiosis and Gateley recognised that there is a gap in the market for a truly comprehensive service that covers all aspects of IP, from its identification to patent protection and commercialisation. I’m looking forward to working with Andrew and the wider team to build this service and provide added value to clients.” Andrew Tingey, who also joins Symbiosis IP from Wellspring, is an experienced dealmaker who has led on, and been involved in, hundreds of commercial agreements involving the licensing and sale of IP rights across life sciences, Greentech, chemicals, and software. Recently nominated in the IAM300 Group for ‘Global leaders in IP strategy’, Andrew has worked with large corporates, SMEs, venture capital firms, and technology transfer offices, and has advised on in and out licensing strategies, complex negotiations and IP valuation projects. During his career, Andrew has been involved in several hundred licensing transactions and the formation of over 60 start-up companies. “Many of the clients that I encounter appreciate how to use IP defensively, but they don’t always understand the art of the possible in terms of releasing the value of that IP,” Tingey said. “Working with the patent attorneys at Symbiosis IP and Adamson Jones, as well as the IP and commercial specialists at Gateley Legal, I hope to flip clients’ thinking so that they see IP, less as an expense, and more as a tool to extend a business’s geographical reach and income potential.”

Addition of A+D® and Solarcaine® bolsters scale, product diversity, and opportunities to accelerate WellSpring's innovation pipeline NEW YORK and SARASOTA, Fla., April 4, 2023 /PRNewswire/ -- WellSpring Consumer Healthcare, a developer and marketer of leading over-the-counter and personal care brands, today announced the acquisition of a portfolio of well-recognized and trusted over-the-counter (OTC) skin care brands from Bayer AG. Financial terms of the transaction were not disclosed. WellSpring Consumer Healthcare is a portfolio company of Avista Capital Partners, a leading middle-market healthcare private equity firm with expertise in building OTC platforms. The brands include A+D®, a leading diaper rash and skin protectant brand, Solarcaine®, the leading sunburn relief brand, and Cortate® and Complex 15®, two Canadian therapeutic skincare brands. A+D® is a widely recognized brand that has been endorsed by pediatricians and trusted by consumers for over 80+ years. Solarcaine® is a pharmacist-recommended medicated burn relief brand that has been relied upon by consumers for generations. Chris Brown, CEO of WellSpring Consumer Healthcare, said: "We are thrilled with the additions of A+D® and Solarcaine®. These trusted, iconic brands align with our core mission to improve the health and wellness of our consumers and will reinforce our position as a leader in important needs-based segments, such as therapeutic skincare. WellSpring's growth model continues to deliver strong results with our focus on new product innovation, distribution expansion, and strategic acquisitions. A+D® and Solarcaine® offer unique opportunities to accelerate our robust product pipeline." Alex Yu, Partner at Avista Capital Partners, said: "This is a highly strategic acquisition for WellSpring, which not only adds established OTC brands to the WellSpring portfolio, but also provides attractive scale, future growth opportunities, and expands our presence in one of WellSpring's core product categories. We are excited for WellSpring to continue building upon the strong heritage of these brands through innovative and high-quality new product development." The acquisition of A+D® and Solarcaine ® represents WellSpring's first add-on acquisition since Avista's investment in WellSpring in August 2022. WellSpring is currently evaluating additional opportunities to further its strong growth trajectory. ABOUT WELLSPRING CONSUMER HEALTHCARE Founded in 1999 in Sarasota, Florida, WellSpring develops and markets a diversified portfolio of trusted OTC brands in the U.S. and Canada, with several that enjoy leading positions in important needs-based product segments such as therapeutic skincare and digestive health. The WellSpring portfolio now includes well-known therapeutic skincare brands such as A+D® (diaper rash and skin protectant), Bactine® (germ-focused skincare) and Solarcaine® (medicated sunburn relief), and category-leaders in digestive health such as Bonine® (motion sickness) and Emetrol® (anti-nausea). WellSpring is an established consumer healthcare platform with a sophisticated omni-channel distribution network that includes leading brick and mortar and e-commerce retailers, a robust new product innovation infrastructure, and a strong growth trajectory. Learn more at . ABOUT AVISTA CAPITAL PARTNERS Founded in 2005, Avista Capital is a leading New York-based private equity firm with over $8 billion invested in more than 40 growth-oriented healthcare businesses globally. Avista partners with businesses that feature strong management teams, stable cash flows and robust growth prospects – investing in the medical devices and technologies, pharmaceuticals, outsourced pharmaceutical services, healthcare technology, healthcare distribution, and consumer healthcare sectors. Avista helps its portfolio companies to accelerate growth through strategic acquisitions, having completed over 100 add-on acquisitions historically across its healthcare portfolio. Avista's Operating Executives and Advisors are an integral part of the team, providing strategic insight, operational oversight and senior counsel, which helps drive growth and performance, while fostering sustainable businesses and creating long-term value for all stakeholders. For more information, visit . Media contacts: Daniel Yunger and Hallie Wolff Kekst CNC 212.521.4800 [email protected] / [email protected] SOURCE Avista Capital Partners

NASHVILLE, Tenn. & BLOOMINGTON, Ind.--( BUSINESS WIRE )--Iron Path Capital, a private equity firm focused on building differentiated businesses in the healthcare and specialty industrials sectors, is pleased to announce that Capitol Pain Institute (CPI) is expanding its quality patient care model through the acquisition of Wellspring Pain Solutions (Wellspring). This partnership is a step forward in CPI’s mission to create a leading national interventional pain management platform. In combination with CPI’s existing clinics and ambulatory surgical centers (ASCs) across Texas, Ohio and Kentucky, the acquisition of Wellspring in Indiana marks a strategic entry into a new state with a highly complementary clinic and ASC footprint. Led by Jeffrey Beck, M.D., Wellspring serves multiple markets across Indiana including Bloomington, Batesville, Columbus, Greenwood, and Terre Haute. "Finding the right partner and alignment was critical to me,” said Dr. Beck. “I am excited for the combined future of our companies and am confident to have chosen the best partner to support our expansion across the region.” “We are thrilled to partner with Wellspring Pain Solutions in the central Indiana market,” said CPI founder and president Matt Schocket, M.D. “Dr. Beck and I share the same goal of providing high-quality, compassionate care to patients. This partnership will allow us to expand our platform in the Midwest and ensure that patients in the region will continue to receive the care they have always relied on," said Dr. Schocket. The need for chronic pain solutions is enormous as the aging population continues to grow. Chronic pain can be debilitating, but interventional procedures and new technologies can give many patients back their mobility and quality of life. CPI and Wellspring offer a comprehensive range of services across the advanced interventional pain management continuum including spinal cord and peripheral nerve stimulation, interspinous stabilization and fixation, the intercept procedure to treat spinal degeneration, and posterior or lateral SI joint fusion. CPI also has an industry-leading compliance system to ensure patients are provided appropriate, personalized, and effective care. “The investment in Wellspring is an extension of the fundamental tenets of our investment in CPI,” said Iron Path Capital co-founder Rob Reistetter. “This partnership reflects a mutual commitment to compliance and advancing healthier alternatives for an in-need population.” This partnership provides mutual benefits to both Wellspring and CPI, their patients and healthcare providers. The combined overall footprint includes clinics and ASCs where patients can receive high-quality care at a lower cost than a traditional hospital setting. Procedures at an ASC can often provide a savings of over 25 percent to both patients and payors. For Wellspring, partnering with CPI allows them to continue their physician-leadership model while enabling the benefits of the overall CPI platform including improved revenue cycle management capabilities, group purchasing agreements, and overall stability with scale. These resources are particularly beneficial for physician practices such as Wellspring as they grapple with the current inflationary environment. “As we continue to support CPI’s growth into a sector-leading platform, it’s important to find the right partners,” said Reistetter. “We look forward to continuing to expand the footprint, providing beneficial resources, and working with top talent in the healthcare field to deliver quality care to patients.” Learn more at CapitolPain.com and IronPathCapital.com . About Capitol Pain Institute Capitol Pain Institute (CPI) is a leading interventional pain management platform with clinics and ambulatory surgical centers across the United States. CPI offers a customized and multi-disciplinary approach to chronic pain treatment, with particular focus on advanced procedures such as spinal cord stimulator implants. CPI partners with physicians and practices that share a common goal of providing high quality, compassionate care at a reasonable cost. The company is also committed to enhancing the communities in which they serve and investing in the advancement of the field of pain management through innovation and evidence-based medicine. CPI was founded by Dr. Matthew Schocket in Austin, Texas in 2007. For more information, visit CapitolPain.com . About Iron Path Capital Iron Path Capital is an operationally focused private equity firm focused on lower-middle-market investments across the healthcare and specialty industrial sectors. With offices in Nashville, TN and Charlottesville, VA, Iron Path Capital supports its partners with capital, operating expertise, business development, and industry relationships to achieve significant scale. Iron Path Capital selects companies with stable cash flows, superior management teams, strong performance trajectories, and multiple vectors for growth, both organic and through consolidation. For more information, visit ironpathcapital.com .